Phase 4 N=44 Conditioned Pharmacotherapeutic Effects in Hypertension
Hypertension
Primary: Mean Systolic Blood Pressure — 151.59; 152.64; 155.42; 151.74 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin
Pain, Postoperative
Primary: Difference in Pain Control When Adding Gabapentin to a Multimodal Pain Management Protocol in Pediatric Post-operative Posterior Spinal Fusion Patients. — 2.46; 3.46…
Phase 4 N=56 Ketamine and Propofol for Upper Endoscopy
Anesthesia
Primary: Dose of Propofol Required to Prevent Movement (Response) to Insertion of Endoscope Into the Patient's Esophagus — 6.1; 4.5; 4.7; 1.1 mg/kg
Phase 4 N=601 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Acellular Pertussis · Tetanus · Poliomyelitis
Primary: Number of Subjects With Vaccine Response Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens — 185; 249; 95; 238 Participants
Phase 4 N=322 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
Age-related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — 8.3; 5.1 Letters — p=<0.001
Phase 4 N=302 Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Primary: Percentage of Participants on LCZ696 200 mg Bid at Month 6 — 64.6 Percentage of Participants
Phase 4 N=3,298 Stress Ulcer Prophylaxis in the Intensive Care Unit
Gastrointestinal Bleeding · Stress Ulcers
Primary: Mortality — 510; 499 Participants
Phase 4 N=50 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
NeuroEndocrine Tumours
Primary: Assessment of Clinical Symptomatic Response — 77.8; 95.5; 87.5; 22.2 Percentage of Subjects — p==0.126
Phase 4 N=281 A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Age-Related Macular Degeneration
Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236
Phase 4 N=268 Effect of Simethicone on Screening Colonoscopy
Adenoma Colon
Primary: Adenoma Detection Rate — 43; 54 adenomas
Phase 4 N=40 Ticagrelor Therapy for RefrACTORy Migraine Study
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Phase 4 N=157 Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)
Spastic Hemiparesis
Primary: Percentage of Responder Participants at Week 6 After the Second Injection, According to Composite Active Range of Motion (AROM) in the Primary TT Limb — 72.1 percentage…
Phase 4 N=46 Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults
Epilepsy
Primary: Overall Composite Z Score of Neuropsychological Battery as a Measure of Direct Comparison of the 2 Antiepileptic Drugs. — .001; -.23 Z-score — p=< .001
Phase 4 N=100 Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage
Atrial Fibrillation
Primary: Percent Confidence in Assessment of Left Atrial Appendage Thrombus — 55; 95 Percentage of Confidence — p=< 0.001
Phase 4 N=11 Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
Cystic Fibrosis
Primary: Peak Plasma Concentration (Cmax) — 2.22; 2.92 mg/liter